Cue Biopharma and ImmunoScape Sign Exclusive In-Licensing Agreement

Written by Emily J. Thompson, Senior Investment Analyst

CUE-2.7%

Updated: Nov 13 2025

0mins

Exclusive Licensing Agreement: ImmunoScape has entered into an exclusive in-licensing deal with Cue Biopharma to develop new therapies targeting solid tumor cancers using Cue's Immuno-STAT molecules.
Innovative Immunotherapy Approach: The collaboration aims to create a "Seed-and-Boost" immunotherapy strategy that enhances the effectiveness of T cell therapies by enabling the in vivo expansion of tumor-targeting T cells.
Targeted Delivery of IL-2: The new strategy allows for the selective delivery of interleukin-2 (IL-2) to tumor-reactive T cells, potentially reducing systemic toxicity associated with current treatments.
Potential Benefits: This approach may streamline manufacturing processes and provide a more durable and effective attack on malignant cells, addressing limitations of existing cell therapies.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like CUE with instant alerts to capture every critical market movement.

CUE

$0.3613+Infinity%1D

Analyst Views on CUE

About CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.